Brokerages Set Centessa Pharmaceuticals plc (NASDAQ:CNTA) Price Target at $25.83

Centessa Pharmaceuticals plc (NASDAQ:CNTA) has been assigned an average recommendation of “Buy” from the six brokerages that are currently covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $25.83.

Several equities research analysts have recently weighed in on CNTA shares. Jefferies Financial Group upped their target price on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. BMO Capital Markets upped their price target on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a report on Monday, September 16th. Oppenheimer reiterated an “outperform” rating and set a $14.00 price objective on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th. Guggenheim upped their target price on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Friday, November 15th. Finally, B. Riley initiated coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, September 19th. They set a “buy” rating and a $33.00 price target on the stock.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 22,205 shares of the stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $15.80, for a total transaction of $350,839.00. Following the transaction, the chief executive officer now owns 663,456 shares of the company’s stock, valued at $10,482,604.80. This trade represents a 3.24 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Gregory M. Weinhoff sold 16,619 shares of the business’s stock in a transaction that occurred on Wednesday, September 25th. The shares were sold at an average price of $15.69, for a total value of $260,752.11. Following the completion of the sale, the insider now owns 206,750 shares of the company’s stock, valued at $3,243,907.50. This trade represents a 7.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 262,624 shares of company stock worth $4,497,698. Insiders own 11.59% of the company’s stock.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in CNTA. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Centessa Pharmaceuticals by 47.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after purchasing an additional 826 shares during the period. GAMMA Investing LLC grew its position in shares of Centessa Pharmaceuticals by 103.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock valued at $48,000 after buying an additional 1,509 shares during the last quarter. Quarry LP raised its stake in Centessa Pharmaceuticals by 47.8% during the second quarter. Quarry LP now owns 9,608 shares of the company’s stock worth $87,000 after acquiring an additional 3,108 shares during the period. Sandia Investment Management LP bought a new position in Centessa Pharmaceuticals in the second quarter worth about $90,000. Finally, Fred Alger Management LLC acquired a new position in Centessa Pharmaceuticals in the second quarter valued at approximately $99,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Stock Down 3.3 %

CNTA opened at $18.06 on Tuesday. Centessa Pharmaceuticals has a 1 year low of $6.15 and a 1 year high of $18.92. The firm has a 50 day moving average price of $16.46 and a 200 day moving average price of $13.09. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The company has a market cap of $2.38 billion, a PE ratio of -11.80 and a beta of 1.52.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. Sell-side analysts expect that Centessa Pharmaceuticals will post -1.6 earnings per share for the current year.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.